Lung Cancer

Eric Kumar Singhi, MD, discusses unmet needs in the management of small cell lung cancer, highlighting how the ADRIATIC study addressed these needs.

Krishnansu S. Tewari, MD, details the current and possible future applications of AI in cancer care as well as the limitations of the technology.

Amivantamab plus chemotherapy has received European approval for EGFR-mutant non–small cell lung cancer that progressed on an EGFR TKI.

Eric Kumar Singhi, MD, discusses potential areas of research interest in the treatment of patients with metastatic lung cancer.

A frontline doublet receives FDA approval in EGFR+ NSCLC, a CRL is issued to linvoseltamab in multiple myeloma, and more this week from OncLive.

Data from the INSIGHT 2 study showed that tepotinib plus osimertinib elicited responses in patients with EGFR-mutated non–small cell lung cancer.

China’s National Medical Products Administration has approved fulzerasib for the treatment of adult patients with advanced KRAS G12C–mutant NSCLC.

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail new trial design proposals for perioperative regimens in resectable NSCLC.

Karen L. Reckamp, MD, MS, discusses emerging EGFR TKIs in EGFR Exon 20–Mutated NSCLC.

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, discuss data with perioperative durvalumab in resectable NSCLC in light of the ODAC decision.

GSK5764227 has received breakthrough therapy designation from the FDA for use in select patients with extensive-stage small cell lung cancer.

An NDA seeking approval of sacituzumab tirumotecan for select patients with EGFR+ non–small cell lung cancer has been accepted by the NMPA's CDE.

The FDA has approved first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

The FDA has granted orphan drug designation to PT217 for the treatment of patients with neuroendocrine carcinoma.

The FDA has lifted a partial clinical hold on the phase 1 trial evaluating YL202 in advanced breast cancer and EGFR-mutated non–small cell lung cancer.

The panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.

Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer.

The FDA has approved neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab, for select resectable non–small cell lung cancer.

Head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Ivonescimab has been granted priority review in China for the frontline treatment of patients with PD-L1–positive locally advanced or metastatic NSCLC.

The FDA granted priority review to durvalumab in limited-stage small cell lung cancer after platinum-based concurrent chemoradiotherapy.

Cameron James Oswalt MD, discusses a study evaluating the timing of palliative care referral and its effect on end-of-life care outcomes in mNSCLC.

Luis E. Raez, MD, FACP, FCCP, discusses the significance of the FDA approval of repotrectinib in solid tumors harboring an NTRK gene fusion.

The FDA has granted fast track designation to Deltacel in combination with low-dose radiation for pretreated metastatic non–small cell lung cancer.

Clinicians specializing in caring for patients with lung cancer discussed clinical trial updates on agents in stage III NSCLC.